Retinoblastoma protein expression predicts response to bacillus Calmette-Guérin immunotherapy in patients with T1G3 bladder cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 28, Issue 3, 2010, Pages 285-289

  Cormio, Luigi ^a   Tolve, Isabella ^a   Annese, Pasquale ^a   Saracino, Alberto ^b   Zamparese, Rosanna ^a   Sanguedolce, Francesca ^a   Bufo, Pantaleo ^a   Battaglia, Michele ^b   Selvaggi, Francesco Paolo ^b   Carrieri, Giuseppe ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

Bladder cancer; Prognosis; Retinoblastoma protein; T1G3

Indexed keywords

BCG VACCINE; RETINOBLASTOMA PROTEIN;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TRANSURETHRAL RESECTION;

ADMINISTRATION, INTRAVESICAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BCG VACCINE; DISEASE-FREE SURVIVAL; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; RETINOBLASTOMA PROTEIN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 77951572370     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2008.08.003     Document Type: Article

References (16)

1. Lebret T., Gaudez F., Hervé, et al. Low-dose BCG instillations in the treatment of stage T1 grade 3 bladder tumors: Recurrence, progression, and success. Eur Urol 34 (1998) 67-72
2. Manoharan M., and Soloway M.S. Optimal management of the T1G3 bladder cancer. Urol Clin North Am 32 (2005) 133-145
3. Malkowicz S.B., Nichols P., Lieskovsky G., et al. The role of radical cystectomy in the management of high grade superficial bladder cancer (PA, P1, PIS, and P2). J Urol 144 (1990) 641-645
4. Herr H.W., and Sogani P.C. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?. J Urol 166 (2001) 1296-1299
5. Saint F., Salomon L., Quintela R., et al. Do prognostic parameters of remission versus relapse after bacillus Calmette-Guérin (BCG) immunotherapy exist? Analysis of a quarter of century literature. Eur Urol 43 (2003) 351-360
6. Logothetis C.J., Xu X.J., Ro J.Y., et al. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J Natl Cancer Inst 84 (1992) 1256-1261
7. Cordon-Cardo C., Wartinger D., Petrylak D., et al. Altered expression of the retinoblastoma gene product: Prognostic indicator in bladder cancer. J Natl Cancer Inst 84 (1992) 1251-1256
8. Cote R.J., Dunn M.D., Chatterjee S.J., et al. Elevated and absent pRB expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 58 (1998) 1090-1094
9. Chatterjee S.J., Datar R., Youssefzadeh D., et al. Combined effects of p53, p21, and pRB expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 22 (2004) 1007-1013
10. Shariat S.F., Tokunaga H., Zhou J., et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 22 (2004) 1014-1024
11. Cordon-Cardo C., Zhang Z.F., Dalbagni G., et al. Cooperative effects of the p53 and pRB alterations in primary superficial bladder tumors. Cancer Res 57 (1997) 1217-1221
12. Grossman H.B., Liebert M., Antelo M., et al. P53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res 4 (1998) 829-834
13. Hitchings A.W., Kumar M., Jordan S., et al. Prediction of progression in pTa and pT1 bladder carcinomas with p53, p16, and pRB. Br J Cancer 91 (2004) 552-557
14. Wang J.Y. Nucleo-cytoplasmic communication in apoptotic response to genotoxic and inflammatory stress. Cell Res 15 (2005) 43-48
15. Ying L., Marino J., Hussain S.P., et al. Chronic inflammation promotes retinoblastoma protein hyperphosphorylation and E2F1 activation. Cancer Res 65 (2005) 9132-9136
16. Ying L., Hofseth A.B., Browning D.D., et al. Nitric oxide inactivates the retinoblastoma pathway in chronic inflammation. Cancer Res 67 (2007) 9286-9293